Efficacy and Safety of Pharmacoprophylaxis for Venous Thromboembolism in Patients Undergoing Bariatric Surgery: a Systematic Review and Meta-analysis

This study aims to assess the efficacy and safety of pharmacoprophylaxis regimens for venous thromboembolism (VTE) in patients undergoing bariatric surgery. A total of 15 studies were included. Low molecular-weight heparins (LMWH) and fondaparinux may be equally effective in reducing VTE risk (OR 1....

Full description

Saved in:
Bibliographic Details
Published in:Obesity surgery 2022-05, Vol.32 (5), p.1701-1718
Main Authors: Zhao, Ying, Ye, Zhikang, Lin, Jianrui, Zhang, Zhiqi, Tian, Peirong, Zhang, Zhongtao, Zhang, Peng, Cui, Xiangli
Format: Article
Language:English
Subjects:
Anticoagulants - therapeutic use
Bariatric Surgery - adverse effects
Disease prevention
Gastrointestinal surgery
Hemorrhage
Heparin, Low-Molecular-Weight - therapeutic use
Humans
Medicine
Medicine & Public Health
Meta-analysis
Obesity, Morbid - surgery
Pulmonary embolisms
Review
Surgery
Thromboembolism
Venous Thromboembolism - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aims to assess the efficacy and safety of pharmacoprophylaxis regimens for venous thromboembolism (VTE) in patients undergoing bariatric surgery. A total of 15 studies were included. Low molecular-weight heparins (LMWH) and fondaparinux may be equally effective in reducing VTE risk (OR 1.02, 95% confidence interval [CI] 0.14–7.39). Pooled estimate suggested uncertain effects of augmented LMWH dosing on VTE prophylaxis compared with standard dosing (OR 0.57, 95% CI 0.07–4.39), but may increase major bleeding (OR 3.03, 95% CI 0.38–23.96). Very low-quality evidence showed an inconclusive effect of extended prophylaxis on VTE (OR 0.54, 95% CI 0.15–1.90) and major bleeding (OR 1.24, 95% CI 0.92–1.68) compared with restricted prophylaxis. Standard LMWH dosing may be effective and safe. Current evidences are insufficient to support extended prophylaxis.
ISSN:0960-8923
1708-0428
DOI:10.1007/s11695-021-05825-9